MIDAZOLAM VIATRIS (midazolam) - Premedication
Opinions on drugs -
Posted on
Jul 29 2024
Reason for request
Reassessment
Summary of opinion
Unfavourable opinion for reimbursement in premedication before induction of anaesthesia in adults and children over the age of 6 months.
Clinical Benefit
Insufficient |
The Committee deems that the clinical benefit of MIDAZOLAM VIATRIS (midazolam) 1 mg/ml and 5 mg/ml solutions for injection or rectal use are insufficient to justify public funding cover in premedication before induction of anaesthesia in adults and children over the age of 6 months in view of the available alternatives. |
Clinical Added Value
Not applicable |
Documents
English version
Contact Us
Évaluation des médicaments